State of Wyoming Has $1.16 Million Position in Globus Medical, Inc. $GMED

State of Wyoming cut its holdings in Globus Medical, Inc. (NYSE:GMED) by 40.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,248 shares of the medical device company’s stock after selling 9,042 shares during the period. State of Wyoming’s holdings in Globus Medical were worth $1,157,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. increased its position in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after buying an additional 167 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in Globus Medical by 2.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 6,316 shares of the medical device company’s stock worth $375,000 after acquiring an additional 170 shares during the period. Parallel Advisors LLC raised its stake in Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares during the period. Finally, Allworth Financial LP boosted its holdings in Globus Medical by 1.6% in the 4th quarter. Allworth Financial LP now owns 12,545 shares of the medical device company’s stock valued at $1,095,000 after purchasing an additional 199 shares during the period. Institutional investors own 95.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GMED. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Royal Bank Of Canada upped their price target on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Finally, Wells Fargo & Company reduced their price objective on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $106.36.

Globus Medical Stock Performance

Shares of GMED stock opened at $77.92 on Thursday. The firm has a fifty day moving average of $86.53 and a 200-day moving average of $88.30. The stock has a market cap of $10.58 billion, a price-to-earnings ratio of 18.12, a P/E/G ratio of 1.61 and a beta of 0.95. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.20. The business had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm’s revenue was up 27.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, sell-side analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.